Evidence map›Paper›PMID 36979099›Full record

ArticleBiology2023

Validation of Recombinant Heparan Sulphate Reagents for CNS Repair.

Susan L Lindsay, Rebecca Sherrard Smith, Edwin A Yates, Colin Cartwright, Bryan E Thacker, Jeremy E Turnbull, Charles A Glass, Susan C Barnett

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Susan L LindsaySchool of Infection and Immunity, Sir Graeme Davies Building, 120 University Place, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0003-4241-4933
Rebecca Sherrard SmithSchool of Infection and Immunity, Sir Graeme Davies Building, 120 University Place, University of Glasgow, Glasgow G12 8TA, UK.
Edwin A YatesInstitute of Systems, Molecules and Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK.ORCID 0000-0001-9365-5433
Colin CartwrightTEGA Therapeutics, Inc., 3550 General Atomics Court, G02-102, San Diego, CA 92121, USA.
Bryan E ThackerTEGA Therapeutics, Inc., 3550 General Atomics Court, G02-102, San Diego, CA 92121, USA.
Jeremy E TurnbullInstitute of Systems, Molecules and Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK.
Charles A GlassTEGA Therapeutics, Inc., 3550 General Atomics Court, G02-102, San Diego, CA 92121, USA.
Susan C BarnettSchool of Infection and Immunity, Sir Graeme Davies Building, 120 University Place, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0003-1009-0575
General Atomics (United States) · USUniversity of Glasgow · GBUniversity of Liverpool · GB

Funding

Medical Research Council MR/V00381X/1Multiple Sclerosis Society 56SPRINT-MND/MS N/A
6 · The paper itself

Abstract

Therapies that target the multicellular pathology of central nervous system (CNS) disease/injury are urgently required. Modified non-anticoagulant heparins mimic the heparan sulphate (HS) glycan family and have been proposed as therapeutics for CNS repair since they are effective regulators of numerous cellular processes. Our

Indexed as

CNS repairheparan sulphateneurite outgrowthrecombinant heparin mimeticsremyelination

Identifiers

PMID36979099
PMCPMC10044841
OpenAlexW4323322643

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read72
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.